Moving to slide nine, At CIT, fourth quarter revenue grew over 19% year over year, evidence of continued progress in both its commercial aerospace and medical technology platforms. Encouragingly, in commercial aerospace, backlog is now at levels not seen since March of 2020. We are encouraged by the growing demand related to narrow-body production driven by steady rebound in global domestic air travel. Longer term, as demand for wide-body production returns with the resumption of international travel, CIT will be well positioned to capture and leverage that growth. Over the past several quarters, CIT has taken significant restructuring actions to drive improved profitability. The impact of these actions has shown over the past several quarters driving CIT's profitability on an adjusted EBITDA basis to swing to positive year-over-year growth in the second half of 2021 as the resumption of revenue growth drives greater leverage. On the medical side, the team delivered record fourth quarter revenue as hospital capital spending resumes. Longer term, as our medical business gains momentum and adds to its current record backlog, we believe the platform is well positioned to drive and leverage mid to high single-digit annual growth going forward.

Feb 10, 2022 / receipt, needs a key / Chris Koch, CEO | earnings call 2022-02-10 | transcript 0c97fd35-3d51-4fc9-bb37-f8e8baee505f | chars 16701-17960 | segment 17

At CIT, we are encouraged by the recovery in narrow-body commercial aircraft and backlog approaching pre-pandemic levels. While the first signs of recovery are encouraging, demand for wide-body aircraft driven by international travel will likely remain muted in 2022. In our medical business, backlog continues to build. Taken together and coupled with the significant restructuring that has occurred at CIT over the past 24 months, CIT is now positioned to leverage what we anticipate would be a sustained recovery. We expect CIT revenue growth to be approximately 10% for full year 2022.

Feb 10, 2022 / receipt, needs a key / Bob, CFO | earnings call 2022-02-10 | transcript 0c97fd35-3d51-4fc9-bb37-f8e8baee505f | chars 23656-24245 | segment 23

At CIT, we are encouraged by the recovery of narrow-body commercial aircraft. While this first step to recovery is encouraging, demand for wide-body aircraft driven by international travel remains muted in 2021. We anticipate this demand will return to previous levels as COVID concerns subside and countries relax their travel restrictions.

Oct 21, 2021 / receipt, needs a key / Chris, CEO | earnings call 2021-10-21 | transcript f945ec2a-2ce7-4fef-ba39-98d80994a0b2 | chars 25503-25844 | segment 25

At least we're seeing increased leisure travel, certainly in the U.S. I know China travel's picked up, too. I've looked at that.

Apr 22, 2021 / receipt, needs a key / Bob, CEO | earnings call 2021-04-22 | transcript 659060c7-1987-4d4c-9e2d-06cf0440d6a3 | chars 38386-38514 | segment 38

I think what has to really start to come back, and hopefully we're going to see that this summer, and I think we feel it will come back, is the business traveler and the international traveler.

Apr 22, 2021 / receipt, needs a key / Bob, CEO | earnings call 2021-04-22 | transcript 659060c7-1987-4d4c-9e2d-06cf0440d6a3 | chars 38557-38750 | segment 38

With higher inoculation rates from rapid vaccine rollouts, easing of COVID travel restrictions, and an improved outlook for both aerospace and hospital capital spending, CIT will drive exceptional leverage with a resumption of growth.

Feb 4, 2021 / receipt, needs a key / Chris, CEO | earnings call 2021-02-04 | transcript 6fa13b6e-e281-4b5d-b394-8c895d433778 | chars 12509-12743 | segment 12

At CIT, we believe that rapid COVID inoculation will drive an improvement in business and leisure travel exiting 2021.

Feb 4, 2021 / receipt, needs a key / Chris, CEO | earnings call 2021-02-04 | transcript 6fa13b6e-e281-4b5d-b394-8c895d433778 | chars 23398-23516 | segment 23

We are following best practices and guidance from recognized authorities on employee health and safety measures, including safe hygiene and social distancing, enhanced facility cleaning and disinfecting, travel and facility access restrictions, and telecommuting where practical.

Apr 21, 2020 / receipt, needs a key / Chris Koch, CEO | earnings call 2020-04-21 | transcript 63946d7e-fc26-4cda-ab05-af95342a6746 | chars 3609-3888 | segment 3

The only impact would be some of the telecommuting or the, I say, travel restraints have hurt some of the new contacts where we'd like to be out there with the engineers working with them in the field.

Apr 21, 2020 / receipt, needs a key / Bob, CEO | earnings call 2020-04-21 | transcript 63946d7e-fc26-4cda-ab05-af95342a6746 | chars 32719-32920 | segment 33